RxDoctor Payments DataLook up a doctor →

Satish Surabhi, MD

Interventional Cardiology · Anderson, SCNPI 1871579888

Payments from drug & device makers

$16,293in general payments, 2019–2025

Across 731 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Inari Medical, Inc.$2K
  • Novartis$1K
  • Abbott$1K
  • Edwards Lifesciences$1K
  • Johnson & Johnson$1K
  • plus $8K from 46 others

What the payments were for

  • Travel & lodging$7675%
  • Food & beverage$15,51495%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,293 in reported general payments places this provider in the 60th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$283,891
Medicare patients
2,449
Services billed
5,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban266$268,127
XareltoRivaroxaban48$44,388
EntrestoSacubitril/Valsartan48$37,168
FarxigaDapagliflozin Propanediol43$36,428
JardianceEmpagliflozin28$26,992
Ranolazine ErRanolazine60$5,475
Valsartan174$5,195
Rosuvastatin Calcium310$3,764
Metoprolol Succinate249$2,821
ClopidogrelClopidogrel Bisulfate268$2,618
Ezetimibe96$2,465
Atorvastatin Calcium196$2,366
Carvedilol258$2,053
Prasugrel Hcl18$1,343
Diltiazem 24hr Er (La)Diltiazem Hcl17$1,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$325$268,127266 claims
Johnson & JohnsonXarelto$1,135$44,38848 claims
NovartisEntresto$1,481$37,16848 claims
AstraZenecaFarxiga$607$36,42843 claims
Boehringer IngelheimJardiance$245$26,99228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →